sh-Polypeptide-4 for Hair Regrowth
Evidence Review created on 11/10/2026 using AI4L + evidence-mcp / Opus 5.5
Also known as: rh-Polypeptide-4, Stem Cell Factor, SCF, KIT Ligand, KITLG, Steel Factor, Mast Cell Growth Factor, Recombinant Human Stem Cell Factor, rhSCF, Ancestim, r-metHuSCF, Stemgen, SLF, MGF
Motivation
sh-Polypeptide-4 is the cosmetic ingredient name for a laboratory-made copy of human stem cell factor, a signaling protein that skin and hair follicles use to coordinate their cells. It is added to scalp serums and lotions sold for thinning hair, often next to other lab-made signaling proteins, and it draws interest because the body’s own supply of this protein takes part in follicle activity and in keeping hair colored.
The protein was first described in blood-cell research, and an injectable version was later tested as a hospital drug for collecting blood stem cells before transplantation. Laboratory work on cells taken from balding scalps, which measured how much of this protein they release, is what brought it into hair-loss products, while newer animal work has asked whether more of it helps or hinders hair growth.
This review examines what is known about sh-Polypeptide-4 as a scalp-applied ingredient for hair regrowth: how it is proposed to act, what human and laboratory evidence exists, its known and theoretical risks, and how its biology compares with the claims made for it, for health-focused adults weighing scalp treatments.
Benefits - Risks - Protocol - Conclusion
Recommended Reading
Five sources give a high-level view of stem cell factor biology in the hair follicle and skin.
-
Stem cell factor/c-Kit signalling in normal and androgenetic alopecia hair follicles - Randall et al., 2008
Dermal papilla cells (signaling cells at the follicle base) from balding scalps secreted less stem cell factor (SCF), which binds the c-Kit growth receptor; the laboratory rationale for SCF in androgenetic alopecia (pattern hair loss).
-
Kit signaling is involved in hair follicle morphogenesis and regeneration in mice - Aoki et al., 2026
Mouse genetic study in which switching on SCF production in follicle cells at the start of the growth phase reversibly delayed hair growth, the main counterweight to the replacement rationale.
-
SCF/c-kit signaling is required for cyclic regeneration of the hair pigmentation unit - Botchkareva et al., 2001
Mouse study in which blocking the SCF receptor produced reversible gray hairs and SCF overexpression increased follicle melanocytes (pigment cells), defining a role in hair color rather than hair growth.
-
Stem cell factor-KIT signalling plays a pivotal role in regulating pigmentation in mammalian hair - Hachiya et al., 2009
From Kao, a cosmetics company: links SCF receptor signaling to human follicle pigmentation and graying, relevant because many SCF hair products also promise color retention.
-
Therapeutic modulation of KIT ligand in melanocytic disorders with implications for mast cell diseases - Sevilla & Grichnik, 2024
Narrative review of how KIT ligand (SCF) controls melanocytes and mast cells, covering hair graying, mastocytosis (mast-cell overgrowth) and melanoma; frames the pigment rationale and the mast-cell and melanoma concerns discussed here.
No directly relevant content on sh-Polypeptide-4 or stem cell factor was found from Rhonda Patrick, Peter Attia, Andrew Huberman, Chris Kresser, Life Extension Magazine or Lifespan.io; these platforms cover supplements and drugs, and the Huberman Lab hair-loss episode covers other treatments without discussing stem cell factor.
Grokipedia
Encyclopedic overview of SCF structure, its KIT receptor and its roles in blood cells, melanocytes and mast cells, useful background for the pigment and mast-cell effects discussed here; it does not cover cosmetic use.
Examine
No Examine article on sh-Polypeptide-4 or stem cell factor exists.
ConsumerLab
No ConsumerLab article on sh-Polypeptide-4 or stem cell factor exists.
Systematic Reviews
One systematic review covers the compound as an intervention, and it concerns injected use, not hair.
-
Systematic review of randomized controlled trials of hematopoietic stem cell mobilization strategies for autologous transplantation for hematologic malignancies - Sheppard et al., 2012
Includes randomized trials of injected recombinant SCF (ancestim) for blood stem-cell collection; relevant to the compound’s risk side, noting higher yields may carry more toxicity.
No systematic review or meta-analysis has examined sh-Polypeptide-4 or stem cell factor for hair regrowth, so the claimed hair benefit is unrepresented in this section.
Mechanism of Action
sh-Polypeptide-4 is recombinant human SCF: a single-chain protein of up to 273 amino acids produced by fermentation in Escherichia coli bacteria (CosIng entry). Its proposed actions all run through one receptor.
- KIT receptor binding: SCF selectively binds KIT, a receptor tyrosine kinase (a cell-surface switch that relays growth signals by adding phosphate groups to proteins), found on melanocytes and on mast cells (immune cells that release histamine).
- Dermal papilla signaling: Scalp dermal papilla cells secrete SCF, and cells from balding follicles secreted less in culture (Randall 2008), the basis for the idea of topping it up.
- Competing growth evidence: Switching on SCF in mouse follicle cells at the start of anagen (the active growth phase) delayed hair growth (Aoki 2026). Mast-cell activation pushed resting mouse follicles into anagen in one study (Paus 1994) and growing follicles into premature catagen (the regression phase) in another (Maurer 1997), so the effect depends on hair-cycle stage.
- Pigment: KIT signaling keeps follicle melanocytes producing color during each growth cycle (Botchkareva 2001).
Pharmacological properties:
- Skin penetration: A protein of this size is far above the roughly 500-dalton (a unit of molecular mass) limit for passive passage through intact skin (Bos 2000), so delivery to the follicle base is uncertain.
- Half-life, distribution, metabolism: No human pharmacokinetic data exist for scalp application. As a protein, it is broken down by proteases (protein-cutting enzymes), not by liver cytochrome P450 enzymes (the main drug-processing enzymes).
Historical Context & Evolution
- Original identification: Amgen scientists identified SCF in 1990 as the product of the mouse Steel gene and the partner of the KIT receptor; given to Steel-mutant mice, it reversed their anemia and mast-cell deficiency (Zsebo 1990).
- Drug development: An injectable recombinant form, ancestim, was tested with filgrastim (a white-blood-cell growth factor) to collect blood stem cells for transplantation; in a 203-patient randomized trial it reduced the collection sessions needed (Shpall 1999). France later offered it on compassionate grounds to patients whose collections had failed (Lapierre 2011).
- Skin observations: Early injection trials recorded skin darkening with more melanocytes (Grichnik 1995) and wheals (raised, itchy welts) with mast-cell degranulation (release of stored histamine) (Costa 1996), which drew dermatology interest.
- Hair interest: Mouse work tied SCF to hair color (Botchkareva 2001), and human balding dermal papilla cells released less of it (Randall 2008).
- Cosmetic era: Biotechnology suppliers now produce it under the INCI (International Nomenclature of Cosmetic Ingredients) name sh-Polypeptide-4; the European Union (EU) inventory lists antioxidant, hair-conditioning and skin-conditioning functions, not hair growth (CosIng entry).
- What changed: Newer mouse data showing that excess SCF can delay hair growth (Aoki 2026) complicate the simple “more is better” premise; no human trial has tested SCF alone for hair.
Expected Benefits
High 🟩 🟩 🟩
No benefit reaches High: no controlled human trial has tested sh-Polypeptide-4 or stem cell factor alone for any hair outcome; the two controlled trials test it only inside an eight-factor mixture.
Medium 🟩 🟩
No benefit reaches Medium: the only controlled human hair data test stem cell factor inside an eight-factor solution given with microneedling, which is indirect evidence capped at Low.
Low 🟩
Hair Density Gain in Pattern Hair Loss ⚠️ Conflicted
An eight-factor SCF-containing solution with microneedling beat saline on hair density in a PnP Biopharm-funded trial of 18 adults (Ro 2016); an independent group saw within-group gains (Quirino 2023). Evidence is indirect: SCF came with seven others. Mouse SCF overexpression delayed growth (Aoki 2026). Net: gains are not SCF-specific.
Magnitude: Hair density rose 21.7/cm² more on the treated side than on the saline side after 3 months (27.1 versus 5.4/cm²; p < 0.05, the p-value being the probability of a difference this large arising by chance) in 18 adults (Ro 2016); no 95% CI (confidence interval, the range likely to hold the true value) reported.
Speculative 🟨
Hair-Cycle Activation via Skin Mast Cells ⚠️ Conflicted
SCF activates human skin mast cells (Costa 1996). In mice, mast-cell activators started anagen in resting follicles (Paus 1994) but hastened catagen in growing ones (Maurer 1997). Basis is mechanistic. Net: effect is stage-dependent.
Hair Pigment Maintenance ⭕️ Not Central to Hair Regrowth
Bears on hair color, not regrowth. Blocking KIT produced reversible gray hairs in mice (Botchkareva 2001) and in human follicle culture (Hachiya 2009). Basis is mechanistic only.
Benefit-Modifying Factors
- Genetic variants: Mutations in KIT (the gene for the SCF receptor) cause piebaldism (inborn white patches of skin and hair) (Ezoe 1995); whether common KIT or KITLG (the SCF gene) variants alter response to added SCF has not been studied.
- Baseline biomarkers: No blood or scalp marker predicts response. Dermal papilla SCF output, the proposed deficit, cannot be measured in routine practice.
- Sex: The balding-cell data came from male scalp follicles (Randall 2008); the controlled scalp trial enrolled 9 men and 9 women and saw no apparent sex difference (Ro 2016), and a second trial found gains in both sexes (Quirino 2023).
- Type of hair loss: The rationale applies to androgenetic alopecia; in chemotherapy-induced hair loss, skin SCF already rises sharply in mice (Sharov 2003), so adding more has no clear basis.
- Age: Graying and pattern loss both increase with age, so older users are the main market; no age-specific response data exist.
- Skin barrier and delivery: Benefit, if any, depends on reaching the follicle base; intact skin largely excludes large proteins (Bos 2000), and microneedling or damaged skin changes this.
Potential Risks & Side Effects
High 🟥 🟥 🟥
No risk reaches High: all human harm data come from injected recombinant stem cell factor in cancer patients, which is indirect by route and dose for a scalp cosmetic.
Medium 🟥 🟥
No risk reaches Medium: the human harm data, randomized trials included, come from subcutaneous injection, which is indirect by route for a scalp product, and the one controlled scalp study of an SCF-containing solution with microneedling reported only minor irritation and tingling (Ro 2016).
Low 🟥
Mast-Cell Activation and Hive-Like Reactions
Injected SCF caused a wheal and flare (welt with redness) at every injection site (Costa 1996); another group recorded five severe mast-cell reactions (Stiff 2000). Evidence is indirect: subcutaneous injection in cancer patients rather than scalp application, so scalp risk is unquantified.
Magnitude: A wheal and flare at each injection site in a 10-patient phase I (first-in-human safety) study (Costa 1996), no control group; severe, non-life-threatening adverse events in 12 of 513 premedicated patients (Lapierre 2011), no control group.
Localized Hyperpigmentation and Melanocyte Overgrowth
Injected SCF increased melanocyte numbers and melanin at injection sites, and its authors advised caution in disorders of melanocyte proliferation, such as many atypical moles (Grichnik 1995). A second group saw darkening last 2–12 months, gradually fading (Costa 1996). Evidence is indirect: injection route; scalp doses are untested.
Magnitude: Persistent hyperpigmentation at injection sites in 5 of 10 patients (Costa 1996), no control group.
Speculative 🟨
Paradoxical Delay of Hair Growth
Switching on SCF in mouse follicle cells at the start of anagen reversibly delayed hair growth (Aoki 2026). Basis is a genetic mouse model only; no human data.
Sensitization to a Bacterially Produced Protein
sh-Polypeptide-4 is made in Escherichia coli (CosIng entry), so residual bacterial proteins could sensitize. Large proteins rarely cross intact skin (Bos 2000). Basis is mechanistic only.
Risk-Modifying Factors
- Genetic variants: Activating KIT mutations such as D816V (a change that keeps the receptor switched on and drives systemic mastocytosis, an overgrowth of mast cells) would add to SCF’s mast-cell stimulation; no study has tested this combination.
- Baseline biomarkers: A raised baseline serum tryptase (an enzyme released by mast cells) signals a larger mast-cell burden and, by inference, a greater chance of hive-like reactions.
- Sex: No sex-based differences in reactions to SCF have been reported; the phase I skin study enrolled only women with breast cancer (Costa 1996), and the lymphoma trial did not report reactions by sex (Stiff 2000).
- Pre-existing conditions: Chronic urticaria (recurrent hives), mastocytosis, many atypical moles or prior melanoma raise concern through SCF’s mast-cell effects (Costa 1996) and melanocyte effects (Grichnik 1995); scalp dermatitis increases penetration.
- Age: No age-specific data exist. Older adults carry more pigmented lesions, which makes baseline skin documentation more useful before scalp use.
Key Interactions & Contraindications
Documented interactions:
- Filgrastim (granulocyte colony-stimulating factor, a drug that boosts white blood cells): Injected SCF added to filgrastim increased blood stem-cell collection yields (Stiff 2000); consequence is additive bone-marrow stimulation, relevant only to systemic exposure. Mitigation: disclosing SCF product use to the treating hematologist.
- Antihistamines (cetirizine, diphenhydramine), albuterol (an airway-opening drug) and pseudoephedrine (a decongestant): All SCF-treated patients received these as premedication, and treatment was generally well tolerated (Shpall 1999); consequence is fewer mast-cell reactions, though severe reactions still occurred (Stiff 2000).
- Microneedling: A split-scalp trial applying an SCF-containing growth-factor solution with microneedling in 18 adults found no side effects beyond minor irritation and tingling (Ro 2016). No interaction found. Mitigation: avoiding needling in people with a history of hives.
Theoretical interactions (inferred from mechanism, not studied in humans):
- KIT-blocking tyrosine kinase inhibitors (cancer drugs that block growth-signal receptors; imatinib, dasatinib, sunitinib): Inferred from blockade of the receptor SCF needs; consequence is loss of any SCF effect. Such drugs can themselves depigment hair (Routhouska 2006). Mitigation: disclosure to the oncologist.
- Mast-cell stabilizers (drugs that stop mast cells releasing histamine; cromolyn sodium, ketotifen) and the flavonoid supplement quercetin: Inferred from inhibition of mast-cell degranulation, which slowed mast-cell-driven hair-cycle changes in mice (Paus 1994); consequence is blunted mast-cell effects.
- Topical retinoids (vitamin A–derived skin agents; tretinoin, over-the-counter retinol): Inferred from retinoic acid raising KIT levels on mouse melanocyte stem cells (Lu 2020); consequence could be a stronger pigment response. Mitigation: application at separate times.
- Other growth-factor serums (epidermal growth factor, fibroblast growth factor 7): Inferred from overlapping growth signaling; consequence is additive growth-signal exposure and possible mast-cell reactions.
- Supplements with an additive effect on KIT signaling: None identified; no supplement is known to raise SCF or KIT activity.
Populations who should avoid sh-Polypeptide-4:
- Systemic mastocytosis or mast cell activation syndrome (recurrent episodes of excess mast-cell mediator release): Inferred from SCF-induced mast-cell growth and degranulation in human skin (Costa 1996); no topical data.
- Prior melanoma or dysplastic nevus syndrome (many atypical moles): Inferred from SCF-driven melanocyte overgrowth at injection sites, whose authors advised caution in disorders of melanocyte proliferation (Grichnik 1995); no data in this group.
- Known allergy to E. coli-derived recombinant proteins: Inferred from production in Escherichia coli (CosIng entry); no human topical data.
- Chronic urticaria with broken or inflamed scalp skin: Inferred from mast-cell activation plus increased penetration through a damaged barrier; no human data.
Risk Mitigation Strategies
Doses and timings below follow common practice unless cited.
- Forearm patch test: Daily application to a small inner-forearm area for 2–3 days before scalp use reveals mast-cell or allergic sensitivity early, preventing a widespread hive-like reaction.
- No needle-based delivery in reactive individuals: Skipping microneedling with SCF serums in people with a history of hives limits the deeper delivery that raises the chance of wheal-and-flare reactions seen with injected SCF (Costa 1996).
- Baseline and 6-month mole photographs: Documenting scalp, hairline and forehead lesions allows early detection of new darkening or melanocyte overgrowth.
- Stop rule for reactions: Use stops at the first hives, persistent redness or new dark patches; spreading welts or breathing symptoms warrant urgent care. Limits mast-cell and pigment harms.
- Shedding check at 8–12 weeks: A clear rise in shedding over baseline is a signal to stop; addresses the paradoxical growth delay seen in mice (Aoki 2026).
Therapeutic Protocol
Timing, frequency, cycling and other parameters below without a citation reflect common practice.
- No established dose: The tested regimen applied an eight-factor solution with SCF at 2.5 µg/mL after 0.5 mm microneedling, every 2 weeks for 6 sessions (Ro 2016); sh-Polypeptide-4 alone is untested.
- Cosmetic approach: Ingredient suppliers with a direct commercial interest market sh-Polypeptide-4 as a hair-growth promoter; leave-on scalp serums are applied once or twice daily.
- Conventional dermatology approach: Clinics treat pattern hair loss with topical minoxidil and oral finasteride, recommended in the European Dermatology Forum’s highest-tier (S3) guideline (Kanti 2018); its dermatologist members prescribe, not sell, these generics. sh-Polypeptide-4 has no role here.
- Procedure-based approach: Clinics combine microneedling or lasers with growth-factor serums, as in a registered trial of a thulium laser combined with a growth-factor serum (NCT07079657); any SCF contribution within such regimens is unknown.
- Time of day: No data favor a time; application to a clean, dry scalp in the evening is common so the product stays on overnight.
- Half-life: No human pharmacokinetic data exist for scalp application; as a protein it is degraded by skin proteases, so daily reapplication is typical.
- Single or split dose: No data compare once-daily with twice-daily use; manufacturers’ instructions vary between the two.
- Genetic polymorphisms: No genetic variant is known to guide use or dose; people with known KIT-activating mutations fall under the populations to avoid.
- Sex differences: No sex difference was apparent in a trial of 9 men and 9 women (Ro 2016), and gains occurred in both sexes in a second trial (Quirino 2023); the rationale rests on male balding-scalp cells (Randall 2008).
- Age: No age-specific data exist; older users with more pigmented lesions benefit most from baseline skin documentation.
- Baseline biomarkers: No biomarker predicts response; iron deficiency or thyroid disease, other causes of shedding, are usually excluded before judging any topical product.
- Pre-existing conditions: The rationale applies to pattern hair loss only; scarring alopecias (hair loss that destroys the follicle) and alopecia areata (patchy hair loss from immune attack) have no SCF-based rationale.
Discontinuation & Cycling
- Duration: No defined course exists; any effect on a follicle signal would be expected to last only while the product is used, so use is open-ended.
- Withdrawal effects: None are known; in mice, hair growth recovered after SCF overexpression (Aoki 2026) and hair color returned after KIT blockade (Botchkareva 2001).
- Tapering: Not applicable; the product can be stopped at once.
- Cycling: No data support cycling for efficacy; pausing is reasonable only to judge whether shedding or pigment changes are product-related.
Sourcing and Quality
- Identity check: Genuine products list “sh-Polypeptide-4” in the ingredients; the EU inventory defines it as recombinant human SCF of up to 273 amino acids made in Escherichia coli (CosIng entry).
- Not a stem-cell product: “Stem cell” serums often contain plant stem-cell extracts or conditioned media instead; these are different ingredients with no SCF guarantee.
- Concentration and position: Growth factors are typically used at very low levels; ingredient-list position near the end is expected, but undisclosed concentration prevents comparison.
- Protein stability: Recombinant proteins degrade with heat and time; airless or refrigerated packaging and clear expiry dates matter.
- Third-party testing: No independent laboratory has published activity testing of sh-Polypeptide-4 products; supplier datasheets are the only quality information, and no brand can be singled out as verified.
Practical Considerations
- Time to effect: Unknown for this ingredient; because hair grows in cycles lasting months, any topical hair product is usually judged after 4–6 months of consistent use.
- Common pitfalls: Confusing the ingredient with stem-cell therapy, expecting regrowth from a hair-conditioning cosmetic, and judging results during normal seasonal shedding.
- Regulatory status (EU): The cosmetic inventory lists only antioxidant, hair-conditioning and skin-conditioning functions for sh-Polypeptide-4, with no restriction recorded (CosIng entry); the human-cell-derived form, rh-Polypeptide-4, falls under Annex II (prohibited substances) (CosIng rh-Polypeptide-4 entry).
- Regulatory status (US): The FDA (US Food and Drug Administration) treats claims that a product will restore hair growth as drug claims, even for products marketed as cosmetics (FDA cosmetic-or-drug guidance).
- Cost and payer incentives: Growth-factor serums usually cost more than generic minoxidil; neither is typically reimbursed for pattern hair loss, so insurer incentives are unlikely to shape this evidence base.
Interaction with Foundational Habits
- Sleep: No direct interaction; nothing suggests SCF affects sleep. Evening application lets a leave-on serum stay undisturbed overnight. Poor sleep worsens stress-related shedding, which can confuse judging any effect.
- Nutrition: Indirect interaction; adequate protein, iron and calories support follicle growth regardless of topical products, and deficiencies cause shedding that no topical protein would correct. No food is known to strengthen or blunt SCF signaling.
- Exercise: No known interaction. Heavy sweating soon after application may dilute or wash off a leave-on serum, so applying after a post-workout shower is a practical choice.
- Stress management: Potentiating interaction through mast cells; CRH (corticotropin-releasing hormone, a stress hormone) raised SCF in human follicles, and blocking SCF stopped the resulting mast-cell degranulation (Ito 2010). Stress pushed mouse follicles toward catagen (Arck 2003). Stress reduction removes this confounder.
Monitoring Protocol & Defining Success
Before starting, a baseline record makes any later change interpretable: standardized scalp photographs from fixed angles, a phototrichogram (magnified photo count of hairs) or trichoscopy (magnified scalp examination) count at a marked site, and photographs of pigmented lesions on the scalp, hairline and forehead. People with a history of hives, flushing or unexplained allergic reactions add a serum tryptase test to screen for a mast-cell disorder.
Ongoing monitoring follows the hair cycle: repeat photographs and counts at 3 and 6 months, then every 6 months while use continues. Skin is checked monthly by the user for new dark patches or changed moles, with dermatology review at 6 and 12 months. Success is a measured gain in density or shaft thickness over the individual’s own baseline at 6 months without reactions or new pigment changes.
| Biomarker | Optimal Functional Range | Why Measure It? | Context/Notes |
|---|---|---|---|
| Hair density and shaft diameter (phototrichogram) | No established target; track change from own baseline at the same marked site | Expected-change marker: the outcome the product claims to change | Phototrichogram (a magnified, standardized photo count of hairs in a marked area); same lighting, part line and hair-wash timing each visit; pair with global photographs |
| Serum tryptase | Below 11.4 ng/mL (standard reference range) | Safety check: a raised value suggests a mast-cell disorder and argues against use | Tryptase is an enzyme released by mast cells; any time of day, no fasting needed; only for people with a history of hives, flushing or anaphylaxis (severe allergic reaction) |
| Pigmented lesion check (dermoscopy) | No established target; record new or changing lesions against baseline photographs | Safety check: new darkening stops use | Dermoscopy (a magnified skin-surface examination); include scalp margins, hairline and forehead, where serum spreads |
Qualitative markers:
- Shedding during washing and brushing compared with baseline
- Scalp itch, redness, burning or hives after application
- Hair texture, thickness and manageability
- Hair color at the roots, including any change in graying
- New dark patches on the scalp margin, forehead or hands
Emerging Research
- No trial of sh-Polypeptide-4: ClinicalTrials.gov lists no registered trial of sh-Polypeptide-4, stem cell factor or KIT ligand for any hair condition as of 11/08/2026; a first controlled scalp trial of SCF alone would be the single most decisive study for health-focused users.
- Peptide-factor serum versus minoxidil (NCT07536100): Randomized, double-blind, 80 participants, 24 weeks, primary endpoint hair density; run with the serum’s maker, MEDEZE Cosmeceutical; recruiting, completion November 2026. Composition is undisclosed. A positive result supports peptide serums generally; a null result weakens the category. Neither isolates SCF.
- Autologous hair follicle secretome (NCT07107841): Sponsored by its developer, Acorn Biolabs; placebo-controlled, 60 participants, injected secretions from the person’s own cultured follicles, primary endpoint target-area hair counts; completion 2027. Positive results support follicle-signal replacement broadly; null results weaken it. Neither isolates SCF.
- Laser plus growth-factor serum (NCT07079657): Thulium laser with growth-factor serum, 30 participants; the record still lists recruiting with an October 2025 estimated completion, but the results are published (Nguyen 2026): hair density rose 22.7% with laser-assisted serum delivery versus 4.9% without serum. Composition undisclosed.
- Timing of KIT signaling: Mouse work shows SCF delays hair growth when switched on at anagen onset but not at catagen (Aoki 2026); human follicle studies of timing and dose could weaken or refine the replacement rationale.
- Lower SCF in balding follicles: The finding that balding dermal papilla cells secrete less SCF rests on a small number of cell lines (Randall 2008); replication in larger human samples could strengthen or overturn the core premise.
Conclusion
sh-Polypeptide-4 is a laboratory-made copy of stem cell factor, a natural signaling protein that helps pigment cells and histamine-releasing immune cells grow and survive. It is sold in scalp serums for thinning hair, usually mixed with other growth factors and rarely at a stated strength.
The case for hair regrowth rests mostly on cell and animal work. Cells from balding scalps appear to release less of this protein, which suggests that adding it back could help. Yet animal work also shows that switching the same signal on at the wrong moment slows hair growth, and its effects on histamine-releasing immune cells can push follicles either toward growth or toward shedding. No human study has applied this protein to the scalp alone, so its contribution cannot be separated from the mixed serums sold. Its clearest role is in keeping hair colored, which is a different goal from regrowth.
Harm data come from people who received the protein by injection for cancer care: hive-like reactions at injection sites and lasting dark patches of skin. Whether a scalp product delivers enough protein through intact skin to cause either is unknown. People with disorders of these histamine-releasing cells, many unusual moles or past skin cancer face the most plausible concern.
The evidence base is thin, largely laboratory-based and partly shaped by ingredient suppliers and cosmetics companies with a commercial stake. For health-focused adults, the ingredient’s benefit for regrowth remains unproven in either direction, while its theoretical risks are modest but not zero.